Literature DB >> 18059183

hTERT-targeted RNA interference inhibits tumorigenicity and motility of HCT116 cells.

Ying Shen1, Yong-Wei Zhang, Zhi-Xiang Zhang, Ze-Hong Miao, Jian Ding.   

Abstract

Telomerase is proposed as an anticancer target. Increasing evidence suggests that telomerase is involved in functions independent of telomere-extension activity. In this study, we designed a small interfering RNA (siRNA) targeting human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase. Using transient and persistent transfection of hTERT siRNA into telomerase-positive human colon carcinoma HCT116 cells, we demonstrated that hTERT siRNA suppresses hTERT expression and leads to inhibition of telomerase activity and HCT116 cell growth and in vivo tumorigenicity in nude mice. Further analysis indicated that depletion of hTERT reduces cell adhesion, migration, and invasion prior to inhibition of cell proliferation. Downregulation of hTERT also decreased the expression levels of adhesion- and motility-related proteins, in particular c-Met and integrins. The lack of detectable changes in telomere length showed that downregulation of hTERT in the present system had no significant effect on telomere-extension activity. Taken together, our results highlight the therapeutic potential of a novel hTERT siRNA and suggest that hTERT is involved in the regulation of cell motility in a telomere-independent manner.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18059183     DOI: 10.4161/cbt.7.2.5259

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  15 in total

Review 1.  Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy.

Authors:  Yunching Chen; Leaf Huang
Journal:  Expert Opin Drug Deliv       Date:  2008-12       Impact factor: 6.648

2.  Inhibition of Telomerase Activity Using an EGFP-Intron Splicing System Encoding Multiple RNAi Sequences.

Authors:  O Sakiragaoglu; A L Munn
Journal:  Mol Biotechnol       Date:  2016-12       Impact factor: 2.695

3.  Small-Molecule-Targeting Hairpin Loop of hTERT Promoter G-Quadruplex Induces Cancer Cell Death.

Authors:  Jin H Song; Hyun-Jin Kang; Libia A Luevano; Vijay Gokhale; Kui Wu; Ritu Pandey; H-H Sherry Chow; Laurence H Hurley; Andrew S Kraft
Journal:  Cell Chem Biol       Date:  2019-05-30       Impact factor: 8.116

4.  Targeted Covalent Inhibition of Telomerase.

Authors:  Rick C Betori; Yue Liu; Rama K Mishra; Scott B Cohen; Stephen J Kron; Karl A Scheidt
Journal:  ACS Chem Biol       Date:  2020-02-24       Impact factor: 5.100

Review 5.  In perspective: An update on telomere targeting in cancer.

Authors:  Eric T Sugarman; Gao Zhang; Jerry W Shay
Journal:  Mol Carcinog       Date:  2019-05-06       Impact factor: 4.784

6.  Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms.

Authors:  Orit Uziel; Einat Beery; Vladimir Dronichev; Katty Samocha; Sergei Gryaznov; Lola Weiss; Shimon Slavin; Michal Kushnir; Yardena Nordenberg; Claudette Rabinowitz; Baruch Rinkevich; Tania Zehavi; Meir Lahav
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

7.  Combination of hTERT knockdown and IFN-gamma treatment inhibited angiogenesis and tumor progression in glioblastoma.

Authors:  Joseph George; Naren L Banik; Swapan K Ray
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

Review 8.  Lipid-based systemic delivery of siRNA.

Authors:  Yu-Cheng Tseng; Subho Mozumdar; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2009-03-26       Impact factor: 15.470

9.  Association of the actin-binding protein transgelin with lymph node metastasis in human colorectal cancer.

Authors:  Ying Lin; Phillip J Buckhaults; Jeffrey R Lee; Hairong Xiong; Christopher Farrell; Robert H Podolsky; Robert R Schade; William S Dynan
Journal:  Neoplasia       Date:  2009-09       Impact factor: 5.715

10.  Targeted gene therapy of nasopharyngeal cancer in vitro and in vivo by enhanced thymidine kinase expression driven by human TERT promoter and CMV enhancer.

Authors:  Cong-Xiang Shen; Zhong Wen; Yu-Hong Qian; Shao-Feng Mu; Xiao-Fang Guan
Journal:  J Exp Clin Cancer Res       Date:  2010-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.